Olmesartán/Amlodipino/Hidroclorotiazida Pensa (Olmesartan Medoxomil, Amlodipine, Hydrochlorothiazide)

Olmesartan medoxomil, amlodipine, and hydrochlorothiazide, the active ingredients in Olmesartán/Amlodipino/Hidroclorotiazida Pensa, are antihypertensive agents presented as oral tablets for oral use. They treat essential hypertension in adult patients, often when single‑agent therapy is insufficient.

GNH USA supplies Olmesartán/Amlodipino/Hidroclorotiazida Pensa as a licensed, GDP‑compliant international pharmaceutical supplier serving pharmacies and clinics worldwide.

Olmesartan/Amlodipine/HCTZ acts on multiple pathways to lower elevated blood pressure in hypertensive patients. - Essential hypertension: provides consistent reduction of systolic and diastolic pressure in adults. - Uncontrolled hypertension: adds therapeutic effect when monotherapy does not achieve target levels. - Hypertension with fluid retention: combines a diuretic to counteract edema associated with calcium‑channel blockade.

Common Side Effects: - Dizziness: transient light‑headedness, especially after dose initiation. - Headache: mild to moderate intensity, often resolves with continued therapy. - Peripheral edema: swelling of ankles due to amlodipine’s vasodilatory effect. - Flushing: temporary warmth and redness of the skin. - Fatigue: general tiredness during early treatment. - Increased urination: diuretic‑related fluid loss.

Serious or Rare Side Effects: - Severe hypotension: marked drop in blood pressure leading to fainting. - Electrolyte imbalance: abnormal potassium or sodium levels, potentially causing cardiac arrhythmia. - Acute kidney injury: reduced renal function, especially in volume‑depleted patients. - Angioedema: rapid swelling of face, lips, or airway requiring emergency care. - Pancreatitis: inflammation of the pancreas presenting with abdominal pain. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis.

Patients should be monitored closely for safety and efficacy when initiating therapy. - Monitor blood pressure: adjust dose to achieve target levels. - Assess renal function: evaluate creatinine and eGFR before and during treatment. - Check electrolytes: especially potassium and sodium concentrations. - Avoid in pregnancy: contraindicated due to risk of fetal toxicity. - Caution with hepatic impairment: dose may need adjustment. - Store at ambient temperature: keep in original container, protect from moisture.

Olmesartan/Amlodipine/HCTZ may interact with several drug classes, requiring careful management. Major Interactions (Avoid): - Potassium‑sparing diuretics: increase risk of hyperkalemia. - ACE inhibitors or ARBs with aliskiren in diabetic patients: heightened adverse‑effect profile. - Lithium: elevated lithium levels and toxicity. - NSAIDs: may blunt antihypertensive effect and impair renal function. Moderate Interactions (Monitor Closely): - Beta‑blockers: additive blood‑pressure lowering effect. - Other thiazide‑type diuretics: potential electrolyte disturbances. - Strong CYP3A4 inhibitors (e.g., ketoconazole): raise amlodipine plasma concentrations.